I am Shin Yong-woo, CEO of DOF Inc, a company that improves the quality of life of mankind.

DOF Inc. bio business started to recognize the reality of domestic patients suffering from inactivation of the domestic tissue donation culture, transplant tissue projects that rely on the import market, and lack of transplant tissue supply.

In order to supply stable domestic transplant tissue, DOF Inc. has been trying to provide the best eco-friendly products and solutions based on biological materials-based supercritical technology through heterogeneous fusion of chemical engineering and biotechnology, and it is gradually paying off.

Based on this, we will develop bio-products such as transplant human tissue, cartilage therapy, tissue-based exosomes, tissue fat-derived fillers, tissue-based medical devices, etc. and build a Regenerative Healthcare Platform that encompasses the next generation bio sector by providing new business expansion and differentiation solutions

We will be a company that strives for sustainable growth. DOF Inc. works with medical professionals and clinicians from relevant medical institutions to ensure safety/validation is complete on each product several times to prevent any possible side effects.

At the same time as non-clinical/clinical, we want to acquire GTP (Organizational Bank) processing and GMP facilities to present optimal health and life to domestic and global customers more effectively and more safely.

Our DOF Inc. executives and employees promise to continue to provide the world's most valuable products and services by growing into a company that improves the quality of life for mankind.

Thank you.

CEO Shin Yong-woo